Drugs Generic: Mylan Inc. (NASDAQ:MYL), Zoetis Inc. (NYSE:ZTS), Actavis plc. (NYSE:ACT), Hospira, Inc. (NYSE:HSP)
Mylan Inc. (NASDAQ:MYL) announced that the Supreme Court of the United States granted certiorari in Mylan’s patent litigation against Teva relating to Mylan’s Abbreviated New Drug Application (ANDA) for glatiramer acetate (Copaxone). In July of 2013, the Court of Appeals for the Federal Circuit ruled that Teva’s U.S. Patent No. 5,800,808 (“the ’808 patent”), along with other patents, was invalid as indefinite. Mylan Inc. (NASDAQ:MYL) shares after opening at $49.68 moved to $50.98 on last trade day and at the end of the day closed at $50.77. Company price to sales ratio in past twelve months was calculated as 2.73 and price to cash ratio as 64.82. Mylan Inc. (NASDAQ:MYL) showed a positive weekly performance of 3.28%.
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (EDT) on Tuesday, May 6, 2014. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Rick Passov will review first quarter 2014 financial results and respond to questions from financial analysts during the call. Zoetis Inc. (NYSE:ZTS) shares advanced 0.92% in last trading session and ended the day on $29.62. Zoetis Inc. (NYSE:ZTS) return on equity ratio is recorded as 61.20% and its return on assets is 8.00%. Zoetis Inc. (NYSE:ZTS) yearly performance is -8.18%.
Actavis plc. (NYSE:ACT) has received a consensus rating of “Buy” from the twenty-three analysts that are covering the company, AnalystRatingsNetwork.com reports. Four research analysts have rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $199.18. Actavis plc. (NYSE:ACT) shares moved down 0.22% in last trading session and was closed at $208.77, while trading in range of $ 207.42 – 211.99. Actavis plc. (NYSE:ACT) year to date (YTD) performance is 24.27%.
Hospira, Inc. (NYSE:HSP), the world’s leading provider of injectable drugs and infusion technologies, will host a conference call to discuss its first-quarter 2014 results on Wednesday, April 30, 2014 at 8 a.m. Central time. Hospira, Inc. (NYSE:HSP) weekly performance is 8.07%. On last trading day company shares ended up $44.19. Hospira, Inc. (NYSE:HSP) distance from 50-day simple moving average (SMA50) is 2.38%. Analysts mean target Price for the company is $42.40.